Alkermes plc (ALKS)
NASDAQ • Healthcare
Last close at November 20, 2026 at 21:00 UTC
Metrics Over Time
Where the Money Goes
Q3 2026In plain terms: out of every $100 in revenue, Alkermes plc keeps $3 as net profit.
Fundamentals & Financials
TTM is calculated as the sum of the four most recently completed quarters. This is a standard approach when monthly or real-time data is not available.
Income Statement
Balance Sheet
Financial Highlights
Dividends History
Split History
Earnings
% — EPS deviation from the forecast (beat / miss); quarters without a forecast show the reported EPS
Alkermes topped expectations on both EPS and revenue in the third fiscal quarter of 2026, reported November 3, 2026, as revenue rose ~22% to roughly $480 million (up from about $394 million a year ago), with EPS of $0.09 topping the -$0.08 estimate by $0.17 and revenue of $480.1 million topping the $463.5 million estimate, +3.6%. Profitability metrics showed a gross margin of ~80% and an operating margin of ~8%, with operating income of about $36 million. Despite the higher revenue, net income fell ~80% year over year to roughly $16 million (down from about $83 million), and EPS was down ~82% from $0.49 a year ago. The company generated about $93.5 million of operating cash flow in the quarter. For the next period, consensus calls for EPS of -$0.13 on revenue of $467.0 million.
About Alkermes plc
Alkermes plc is a biotechnology company listed on NASDAQ as ALKS that develops and commercializes central nervous system medicines and related drug-delivery capabilities. Its portfolio spans schizophrenia, addiction, bipolar disorder, and sleep disorders, and it generated $1.5 billion of revenue in FY2025.
Today's Snapshot
ALKS closed 2.7% lower at 44.94, while its sector was flat.
Trading Volume
Below 10d avg (1.4M)
1M
vs S&P 500 Today
Outperforming Market
+0.80%
Updated: November 20, 2026 at 21:16 UTC
Technical Indicators
All signalsHide signals
- EMA (5 indicators)$40.33 - $46.01Sell
- RSI (14)48.50Neutral
- Stochastic %K (14, 3, 3)45.39Neutral
- MACD Level (12, 26)0.67Neutral
Peers & Related Assets
Get premium market insights delivered directly to your inbox.